Raleigh, NC (PRWEB) December 08, 2015 -- In the wake of the FDA approval of Keytruda (pembrolizumab) for non-small cell lung cancer, researchers in Toronto have released an overview of the drug and its potential for treating other cancers, including mesothelioma. Surviving Mesothelioma has just posted an article on the new report. Click here to read it now.
In October, Keytruda was approved to treat non-small cell lung cancer by targeting cancer cells expressing a protein called PD-1.
In an article in Future Oncology, Drs. Safiya Karim and Natasha Leighl with Toronto's Princess Margaret Cancer Center explore Keytruda's potential for treating other cancers, such as malignant pleural mesothelioma, that express the same protein.
“Pembrolizumab is a PD-1 inhibitor that has shown clinical activity in a variety of solid tumors,” note the researchers.
“Because there are so few viable treatment options for patients with mesothelioma, the mesothelioma community is naturally very excited about the future possibilities for Keytruda. We'll be following news of this drug closely,” says Alex Strauss, Surviving Mesothelioma’s Managing Editor.
To read more about the Canadian report and the results of mesothelioma clinical trials with Keytruda, see Mesothelioma Community Hopeful About Newly Approved Immunotherapy Drug, now available on the Surviving Mesothelioma website.
Karim, s and Leighl, N, “Pembrolizumab for the treatment of thoracic malignancies: current landscape and future directions”, December 3, 2015, Future Oncology, Epub ahead of print, http://www.futuremedicine.com/doi/abs/10.2217/fon.15.294
For nearly ten years, Surviving Mesothelioma has brought readers the most important and ground-breaking news on the causes, diagnosis and treatment of mesothelioma. All Surviving Mesothelioma news is gathered and reported directly from the peer-reviewed medical literature. Written for patients and their loved ones, Surviving Mesothelioma news helps families make more informed decisions.
Michael Ellis, Cancer Monthy, http://www.survivingmesothelioma.com, +1 (919) 570-8595, [email protected]
SOURCE Cancer Monthy